64 results about "Rotavirus Infections" patented technology

The present invention relates to novel recombinant polypeptide antigens that may comprise subunit vaccines against rotavirus infection. Further, the present invention relates to methods for use of said antigens in the diagnosis, treatment and prevention of rotavirus infection.

The present invention relates to a Lactobacillus reuteri variant from animal sources that inhibits rotavirus infection and other pathogenic microorganisms, as well as being tolerant of gastric and bile acids. Also, this invention relates to a prophylactic and therapeutic composition comprising the same for contributing in many probiotic ways to the host's general health and preventing and treating diseases or conditions associated with rotavirus and other enteric pathogens.

Compositions and methods related to live or live attenuated pre-conditioned and typical viruses such as rotaviruses are disclosed. The live attenuated rotaviruses exhibit better stability characteristics and are useful for the prevention of a rotavirus infection and / or rotavirus gastroenteritis in children.

The present invention relates to a combined norovirus and rotavirus vaccine for prevention of norovirus and rotavirus infection and / or viral-induced diarrheal and vomiting diseases in man. More specifically, the invention comprises a method of preparing combination vaccine compositions comprising norovirus and rotavirus antigens, in particular mixtures of norovirus VLPs and rotavirus recombinant VP6 protein or double-layered VP2 / VP6 VLPs. In addition, the invention relates to methods of inducing an immune response.

The present invention relates to polymerizable monomers for applications in medicine and biotechnology and synthesis thereof. The polymerizable ligands containing NAcetyl Glucosamine bind more strongly to lysozyme than NAG itself. The binding is further enhanced when a spacer arm, for example 6-Amino Caproic Acid (6-ACA) is introduced in the structure. The conjugated ligands could be used for prevention and treatment of bacterial and viral infections Moreover these ligands can be coupled to stimuli sensitive polymers and used for the recovery of biomolecules The methodology can be extended to other ligands such as sialic acid and the corresponding polymers used for preventil1g influenza and lor rotavirus infections

The invention discloses application of 4', 5, 7-genistein in preparing rotavirus resisting medicine. The genistein can restrain damage of tyrosine protein kinase to cell junction by restraining activation, caused by rotavirus infection, of tyrosine protein kinase of intestinal epithelial cells, so that the intestinal epithelial cells are prevented from being damaged by rotavirus, the completeness of intestinal mucosa is protected, the symptom of rotavirus diarrhea is obviously reduced, and the lethality is reduced. Thus, when the genistein is used as a main active ingredient, high-efficient and low-toxicity specificity rotavirus diarrhea resisting medicine can be researched and developed hopefully.

The invention relates to a building method of a rotavirus infection suckling mouse experiment model. The method concretely comprises the following steps that 7-day-old ICR suckling mice are used as experimental animals; a 1ml improved injector is used; 0.2ml of rotavirus liquid is given in an intragastric administration mode. The model provided by the invention can simulate features of infant rotavirus infection acute gastroenteritis; the rotavirus infection suckling mouse experiment model is fast built; the sufficient number of mice infecting the rotavirus are obtained; the stability is good; the repeatability is realized; the model building success rate is high and is nearly 100 percent. In addition, the technical scheme provided by the invention has the advantages that the weight of the selected low-age animals is light; the obtaining is easy; the used virus dose is small; the experiment cost is reduced; the method is applicable to batch modeling.

The invention relates to pichia pastoris for expressing rotavirus expression particles as well as a preparation method and application of the pichia pastoris, and discloses a human rotavirus structural protein expression cassette, comprising the following elements: (a) an initial signal element AOX; (b) a rotavirus structural protein gene; and (c) a termination signal element TT. The invention further discloses a yeast cell transfected by using the expression cassette, a method for preparing the rotavirus viroid particles by using the yeast cell, viroid particles prepared by using the method, and application of the viroid particles for preparing vaccine compositions for preventing or treating rotavirus infection. The invention also discloses a preparation method of the yeast cell.

The present invention discloses one coding gene of rotavirus VP6 protein and its application, and aims at providing one coding gene of rotavirus VP6 protein with high expression amount in dicotyledonous plant, especially clover, method of producing oral rotavirus vaccine with the coding gene and the obtained oral vaccine. The rotavirus VP6 protein coding gene has one of the following nucleotide sequences: 1. DNA sequence of SEQ ID No. 1 in the sequence list; 2. DNA sequence of SEQ ID No. 2 in the sequence list; 3. the nucleotide sequence capable of hybridizing in high strict condition with the DNA sequence limited by SEQ ID No. 1 or SEQ ID No. 2; and 4. DNA sequence possessing over 80 % homology with the SEQ ID No. 1 or SEQ ID No. 2 limited DNA sequence and high expression amount in dicotyledonous plant. The oral rotavirus vaccine is used in preventing various rotavirus infection caused acute diarrhea of infant and young animal.

The present invention relates to a VP7 gene of human rotavirus and a composition for diagnosis of human rotavirus infection comprising primer or probe specific to thereof, and more particularly to a VP7 gene encoding the amino acid sequence set forth in SEQ ID NO:2 and a composition for diagnosis of human rotavirus infection comprising primer or probe specific to thereof. The human rotavirus VP7 gene according to the present invention will be useful for diagnosis of novel G11 type human rotavirus infection, and will be used for development of rotavirus vaccine.

The present invention relates to polymerizable monomers for applications in medicine and biotechnology and synthesis thereof. The polymerizable ligands containing nacetyl glucosamine bind more strongly to lysozyme than nag itself. The binding is further enhanced when a spacer arm, for example 6- amino caproic acid (6-aca) is introduced in the structure. The conjugated ligands could be used for prevention and treatment of bacterial and viral infections. Moreover these ligands can be coupled to stimuli sensitive polymers and used for the recovery of biomolecules. The methodology can be extended to other ligands such as sialic acid and the corresponding polymers used for preventing influenza and for rotavirus infections.

The invention discloses application of stachyose in preparing a medicine for preventing and curing diarrhea. Experiments prove that the stachyose has certain alleviating and curing effects for intestinal infection diarrhea, antibiotic-associated diarrhea, bacillary dysentery diarrhea, rotavirus infection diarrhea, non-specific diarrhea and the like.

The invention discloses a method for simultaneously detecting three groups of rotaviruses A, B and C, and belongs to the field of biological detection. A pair of specific primers and a specific probewith different fluorescent labels are designed for target genes of group A rotavirus, group B rotavirus and group C rotavirus, a pair of universal primers is further designed, and during PCR amplification, the specific primers with universal primer tags are used for enrichment and amplification; and then universal primer tags are used for exponential amplification, and fluorescence signals of exponential amplification products are collected for detection. The method can simultaneously detect the group A rotavirus, the group B rotavirus, and the group C rotavirus. The method is high in specificity, high in sensitivity and short in detection time, and can be used for early rapid diagnosis of rotavirus infection and epidemiological study of the rotavirus.

The present invention relates to novel recombinant polypeptide antigens that may comprise subunit vaccines against rotavirus infection. Further, the present invention relates to methods for use of said antigens in the diagnosis, treatment and prevention of rotavirus infection.

Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunisation method, rotavirus detection method, vaccine composition, prevention and treatment methods for rotavirus infections, wherein said domain may be any of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, and wherein said domains bind to protein VP6 of Group A rotavirus.

A method for inhibiting Rotavirus infection by administering effective amount of lactulose is provided. Lactulose can be administered alone, in combination with other nutrient supplements such as vitamins, or as part of a nutritional product such as infant formula.

The invention provides application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of drugs or food for resisting rotavirus infection induced diarrhea. The medicine or food for resisting diarrhea caused by rotavirus infection comprises a bifidobacterium animalis subsp. Lactis BLa80 microbial inoculum. The bifidobacterium animalis subsp. Lactis BLa80 microbial inoculum is pure bifidobacterium animalis subsp. Lactis BLa80 or a composition of the bifidobacterium animalis subsp. Lactis BLa80 and a protective agent, and the protective agent comprises an emulsifier, polysaccharide and glycerol. The medicine or food for resisting diarrhea caused by rotavirus infection is free of toxic and side effects, free of immune stress and free of drug resistance, can inhibit infection and proliferation of rotavirus on cells in vitro, has an excellent rotavirus resisting effect, and can effectively relieve diarrhea symptoms caused by rotavirus infection.

Rotavirus is a virus capable of causing acute gastrointestinal diseases (diarrhea). The invention discloses a nano antibody targeting rotavirus capsid protein as well as expression, purification and identification of the nano antibody. The nano antibody targeting the rotavirus can be used for environment monitoring of the rotavirus and clinical diagnosis and treatment of rotavirus infection.

The present invention relates to a composition for preventing or treating rotavirus infection containing licorice extract, fractions of the extract or a compound separated from the extract. The licorice extract, fractions of the extract or a compound separated from the extract have anti-rotaviral effects, and exhibit, against a variety of rotaviruses, virucidal effects and inhibitory effects on cell degeneration at the same time, and therefore can be valuably used in preventing or treating rotavirus infection.

The invention belongs to the field of biological medicine, and particularly relates to a rotavirus exosome and application thereof. At present, related reports about whether exosomes are secreted after rotavirus infects host cells or not and the regulation mechanism of the exosomes in the virus replication process do not exist. The invention discloses an exosome containing miR-135b-5p and an application of the exosome in inhibiting rotavirus infection, including an application in preparing a drug for treating rotavirus and a reagent for neutralizing rotavirus.

The invention discloses probiotic powder containing human body homologous strains and application of the probiotic powder, and belongs to the technical field of microorganisms and the technical field of medicines. The probiotic powder is composed of bifidobacterium bifidum BGN4, bifidobacterium longum BORI, bifidobacterium lactis AD011, lactobacillus rhamnosus BH09, dual prebiotics and 13 basic nutrients, can regulate intestinal flora disorder of children, and is specifically embodied in that the probiotic powder can improve the intestinal micro-ecological environment, prevent rotavirus infection, improve the immunity of children, and improve the immunity of children. The composition can prevent and relieve children eczema and allergic dermatitis, relieve diarrhea, constipation and other intestinal problems, improve lactose intolerance and effectively eliminate toxins in food. Therefore, the probiotic powder containing the bifidobacterium bifidum BGN4, the bifidobacterium longum BORI, the bifidobacterium lactis AD011 and the lactobacillus rhamnosus BH09 has a great application prospect in regulating the intestinal flora disorder of the children.

The invention provides application of a berberine and bacillus licheniformis composition in preparation of a drug for preventing or treating diseases caused rotavirus infection and relates to the field of drug compositions and novel application thereof. The berberine and bacillus licheniformis composition is used for preventing or treating enteritis, diarrhea and other diseases caused by rotavirus infection and has the advantages of being efficient, low in toxicity and the like.

The invention belongs to the technical field of microorganisms, and discloses a Real-time PCR quantitative detection method for human group H rotaviruses. An upstream primer F for Real-time PCR quantitative detection comprises SEQ ID No.1 and a sequence which at least has 70% of homology with the SEQ ID No.1; a downstream primer R comprises SEQ ID No.2 and a sequence which has at least 70% of homology with the SEQ ID No.2; and the probe comprises SEQ ID No.3 and a sequence which has at least 70% of homology with the SEQ ID No.3. The Real-time PCR circulation conditions are as follows: reverse transcription is performed for 5-8 minutes at 48-55 DEG C, PCR initial activation is performed for 20-50 seconds at 95 DEG C, denaturation is performed for 10-20 seconds at 95 DEG C, annealing and extension are performed for 50-70 seconds at 55-65 DEG C, 35-45 cycles are performed, and a fluorescence signal is detected after each cycle. The method can be used for rapidly and effectively detecting the human group H rotavirus infection. The detection method provided by the invention has relatively high detection sensitivity and specificity, is simple to operate and convenient to apply, and provides feasible technical support for group H rotavirus monitoring and group H rotavirus infection disease prevention and control in the fields of clinical diagnosis, inspection and quarantine and the like.

The invention relates to application of shikonin to preparation of rotavirus infection resisting drugs. The shikonin, or pharmacologically acceptable salt, ester and solvate thereof finally achieve the beneficial effect of rotavirus resistance by inhibiting replication and amplification of rotaviruses and inhibiting antigen synthesis of the rotaviruses; and the shikonin, or the pharmacologically acceptable salt, ester and solvate thereof have no toxic and side effect on normal cells, are good in safety, provide a theoretical basis for studying the treatment strategy of rotavirus infection, andprovide an embedding point for preparation of the new rotavirus-resisting drugs.

The invention discloses a preparation method of an anti-porcine rotavirus egg yolk antibody. The preparation method comprises the following steps that an RVA inactivated vaccine for immunization is injected, continuously immunizing is carried out for 4 times at an interval of 2 weeks, after two immunizations, when the neutralizing titer of the antibody reaches 1: 200 or above, it is considered that the immunization is qualified, eggs are collected every day, marking is carried out, storing is carried out at 4 DEG C for later use, and the egg yolk antibody IgY is extracted. The egg yolk antibody has a certain effect on prevention and treatment of piglet RVA, can remarkably shorten the disease course, and can be used for preparing products for detecting, preventing and / or treating related diseases caused by porcine rotavirus infection.

The present invention relates to synthetic fucosylated oligosaccharide for use in the treatment or prophylaxis of an infection with a Norwalk-like Virus or Rotavirus of a mammal, wherein the synthetic fucosylated oligosaccharide comprises a non-reducing end and an reducing end, wherein the reducing end comprises a first carbohydrate unit consisting of a galactose (Gal) linked via a ²1-4 glycosidic bond to a glucose (Glc), and wherein the non-reducing end comprises a second carbohydrate unit linked via a ²1-3 glycosidic bond to the first carbohydrate unit of the reducing end, and wherein the second carbohydrate unit comprises a) at least one or more of a fucose (Fucose) and a Galactose (Gal), and b) at least one or more of a N-acetylglucosamine (GlcNAc) or a N-acetylgalactosamine (GalNAc).

A deactivated tetravalent rotavirus vaccine for preventing the infantile rotavirus infections diseases is prepared from the calf kidney cells digested and dispersed by pancreatin or cultured Vero cells through inoculating rotaviruses G1, G2, G3 and G4, culturing in non-serum culture liquid D-MEM, concentrating, purifying, deactivating, mixing and adding aluminium hydroxide.